Literature DB >> 7863986

Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris.

J G Diodati1, R O Cannon, N Hussain, A A Quyyumi.   

Abstract

This study assessed the inhibitory effect of nitroglycerin and sodium nitroprusside on platelet aggregation in a model of platelet activation across coronary circulation. Platelet aggregation is believed to contribute to the precipitation of acute ischemic syndromes. We previously showed that rapid atrial pacing in patients with stable coronary artery disease (CAD) causes platelet hyperaggregability during blood passage in coronary circulation. Because nitroglycerin and sodium nitroprusside have been shown to inhibit platelet aggregation, we examined the effect of these drugs on this model of platelet activation. During catheterization of 19 patients with CAD (> 50% diameter narrowing of epicardial coronary arteries), we measured platelet aggregation (using whole blood platelet aggregometry) on blood samples obtained simultaneously from the coronary sinus and aorta at rest, and 2 minutes after onset of rapid atrial pacing. This procedure was repeated during an intravenous infusion of either nitroglycerin (n = 9) or sodium nitroprusside (n = 10). There was no arteriovenous difference in platelet aggregation under resting conditions. Atrial pacing caused an increase in platelet aggregation in coronary sinus blood (+64 +/- 9%; p < 0.01), but not in arterial blood (15 +/- 12% decrease; p = NS). This increase was transient and returned toward baseline 10 minutes after termination of pacing. Although resting platelet aggregation was not affected by nitroglycerin or sodium nitroprusside, activation of platelets with atrial pacing across the coronary bed was stopped by pretreatment with therapeutic doses of nitroglycerin or sodium nitroprusside. When coronary blood flow increases in patients with CAD, platelets are activated and aggregate more easily. This activation can be blunted by pretreatment with nitroglycerin or sodium nitroprusside.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7863986     DOI: 10.1016/s0002-9149(99)80578-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.

Authors:  Andrew S Holmes; Yuliy Y Chirkov; Scott R Willoughby; Susan Poropat; Jeremy Pereira; John D Horowitz
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

2.  Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris.

Authors:  Y Y Chirkov; L P Chirkova; J D Horowitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

3.  A Novel Nonantibiotic Nitroglycerin-Based Catheter Lock Solution for Prevention of Intraluminal Central Venous Catheter Infections in Cancer Patients.

Authors:  Anne-Marie Chaftari; Ray Hachem; Ariel Szvalb; Mahnaz Taremi; Bruno Granwehr; George Michael Viola; Sapna Amin; Andrew Assaf; Yazan Numan; Pankil Shah; Ketevan Gasitashvili; Elizabeth Natividad; Ying Jiang; Rebecca Slack; Ruth Reitzel; Joel Rosenblatt; Elie Mouhayar; Issam Raad
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  Ascorbate attenuates red light mediated vasodilation: Potential role of S-nitrosothiols.

Authors:  Agnes Keszler; Brian Lindemer; Neil Hogg; Nicole L Lohr
Journal:  Redox Biol       Date:  2018-09-10       Impact factor: 11.799

Review 5.  Influence of Cardiometabolic Risk Factors on Platelet Function.

Authors:  Cristina Barale; Isabella Russo
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

6.  Integrated microRNA‑gene analysis of coronary artery disease based on miRNA and gene expression profiles.

Authors:  Xiangdong Xu; Hongsong Li
Journal:  Mol Med Rep       Date:  2016-02-23       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.